170 North Radnor-Chester Road
United States - Map
PolyMedix, Inc., a clinical stage biotechnology company, focuses on developing synthetic small molecule compounds for the treatment of patients with acute care conditions. The company is developing defensin-mimetics antibiotics for the treatment of life-threatening infections. Its compounds are designed to imitate the mechanism of action of host defense proteins, which contribute to natural human immunity. It lead product candidate includes brilacidin, an antibiotic agent that is in Phase 2 clinical trial for acute bacterial skin and skin structure infections (ABSSSI) caused by either drug-sensitive or drug-resistant strains of Staphylococcus aureus bacteria. The company has plans to initiate a Phase 2B dose optimization study with brilacidin in ABSSSI patients and also to develop brilacidin as a topical treatment for oral mucositis, a common and often debilitating complication of cancer treatments. PolyMedix has internally developed a pipeline of compounds, including other defensin-mimetic antimicrobial compounds for other infectious diseases, such as Gram-negative pathogens, fungal infections, and malaria; PolyCides, which are antimicrobial additives to create self-sterilizing products and surfaces; and delparantag, an anticoagulant reversing agent to restore coagulation and reduce the incidence of bleeding in Percutaneous Coronary Intervention procedures. The company was founded in 2002 and is headquartered in Radnor, Pennsylvania. On April 1, 2013, PolyMedix, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
|Dr. Richard W. Scott Ph.D.,
Founder and VP of Research
|Dr. Daniel M. Jorgensen M.D.,
Chief Medical Officer and Sr. VP of Clinical Devel.
|Dr. Bozena Korczak Ph.D.,
VP of Devel.
|Ms. Lisa M. Caperelli ,
Director of Investor Relations & Corp. Communications
|Ms. Dawn Porter Eringis ,
VP of Commercialization & Scientific Affairs
|Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|